NFKB1 and cardiovascular disorder: Furthermore, SFN modulates the MAPK/AP-1/NF-κB pathway, reducing the activation of specific kinases (p38, ERK, JNK) and inhibiting NF-κB, with beneficial effects on inflammation associated with cardiovascular diseases [105].